Therapy News and Research

RSS

UCLA researchers find decrease in overall mortality rates for advanced heart failure

UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden cardiac death, caused by the rapid onset of severe abnormal heart rhythms, has declined.

24 May 2013

Researchers discover how drug prevents cancer progression

In collaboration with Daniel Zenklusen, also a University of Montreal biochemistry professor and lead author and doctoral candidate Vincent Messier, discovered that when cells are starved for nutrients TOR sends a signal to shut down production of a chemical message in the form of RNA to synthesize B cyclin ", Dr. Michnick explained.

24 May 2013

Merck updates on preladenant clinical program for treatment of Parkinson's disease

Merck, known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease.

24 May 2013

Researchers explore targeted therapies for prostate cancer

Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients – the next question is to figure out how to match the right treatments with the right patients.

24 May 2013

SonaCare Medical highlights need for image-guided technologies to better identify prostate cancer

The need to add tissue preserving therapies to the prostate cancer treatment continuum was highlighted prominently at the 108th Annual Meeting of the American Urological Association, in San Diego.

24 May 2013

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection.

24 May 2013

Drug addiction can be visualized in specific regions of brain that determine decision-making

New research shows that craving drugs such as nicotine can be visualized in specific regions of the brain that are implicated in determining the value of actions, in planning actions and in motivation.

24 May 2013

New study determines that children with temporal lobe epilepsy likely to have depression

A new study determined that children and adolescents with seizures involving the temporal lobe are likely to have clinically significant behavioral problems and psychiatric illness, especially depression.

24 May 2013

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

23 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

Arthritis Research UK awards Cardiff researchers a grant to develop new drugs to treat osteoarthritis

Medical research charity Arthritis Research UK has awarded a team of researchers at Cardiff University a grant of £200,000 to investigate new drugs to treat early onset osteoarthritis. The team will investigate a new therapy to reduce the risk of developing osteoarthritis.

23 May 2013

CardioKinetix reports meta-analysis study results of Parachute Ventricular Partitioning Device

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced results of a meta-analysis study of the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device. Six-month clinical results from 91 U.S. and European patients with ischemic heart failure were presented at the 2013 EuroPCR Conference in Paris by Dr. Martyn Thomas, M.D., chairman of Cardiology at St. Thomas Hospital in London, England.

23 May 2013

Johns Hopkins researchers find possible trigger of rheumatoid arthritis

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe cases of the disease, the immune system makes a unique subset of antibodies that have a disease-promoting role.

23 May 2013

$Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS$

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.

23 May 2013

Physicists demonstrate effect of cold atmospheric plasma, chemo therapy on brain tumour cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.

23 May 2013

Cancer experts to discuss latest developments and implications of cell therapies in oncology

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

23 May 2013

Researchers find that over 40% of patients treated for COPD did not actually have the disease

More than 40 percent of patients being treated for COPD at a federally funded clinic did not have the disease, researchers found after evaluating the patients with spirometry, the diagnostic "gold standard" for chronic obstructive pulmonary disease.

23 May 2013

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Northwestern University researchers have developed a new method for delivering molecules into single, targeted cells through temporary holes in the cell surface. The technique could find applications in drug delivery, cell therapy, and related biological fields.

22 May 2013

A1-PI treatment slows progression of emphysema in patients with AATD

Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.

22 May 2013

Mayo Clinic expert offers tips for children with weather-related fears

Violent storms — often accompanied by lightning, thunder, heavy rain, powerful winds and even tornado warnings — can be stressful for anyone, but severe weather can trigger much more severe anxiety, especially among children.

22 May 2013

Therapy News and Research

UCLA researchers find decrease in overall mortality rates for advanced heart failure

Researchers discover how drug prevents cancer progression

Merck updates on preladenant clinical program for treatment of Parkinson's disease

Researchers explore targeted therapies for prostate cancer

SonaCare Medical highlights need for image-guided technologies to better identify prostate cancer

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Drug addiction can be visualized in specific regions of brain that determine decision-making

New study determines that children with temporal lobe epilepsy likely to have depression

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Arthritis Research UK awards Cardiff researchers a grant to develop new drugs to treat osteoarthritis

CardioKinetix reports meta-analysis study results of Parachute Ventricular Partitioning Device

Johns Hopkins researchers find possible trigger of rheumatoid arthritis

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

Physicists demonstrate effect of cold atmospheric plasma, chemo therapy on brain tumour cells

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Researchers find that over 40% of patients treated for COPD did not actually have the disease

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

A1-PI treatment slows progression of emphysema in patients with AATD

Mayo Clinic expert offers tips for children with weather-related fears

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News